← All indications
Gastrointestinal Diseases
Diseases in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.
Subtype terms (9)
More specific conditions that are subtypes of Gastrointestinal Diseases in the MeSH hierarchy.
- Esophageal Diseases
54 drugs (35 approved, 19 experimental)
- Gastroenteritis
59 drugs (22 approved, 37 experimental)
- Gastrointestinal Hemorrhage
28 drugs (24 approved, 4 experimental)
- Gastrointestinal Neoplasms
172 drugs (91 approved, 81 experimental)
- Intestinal Diseases
126 drugs (78 approved, 48 experimental)
- Rumination Syndrome
1 drug approved
- Stomach Diseases
104 drugs (68 approved, 36 experimental)
- Tuberculosis, Gastrointestinal
- Visceral Prolapse
Drugs by status
Approved for this indication (11)
Phase 4 trials (16)
Phase 3 trials (21)
Phase 2 trials (40)
- anlotinib
- anti-interferon-gamma monoclonal antibody
- human fibrin
- crofelemer
- da jian zhong tang
- daclizumab
- fluorouracil
- Iberis amara
- ganciclovir
- iw-9179
- khk4083
- mazirenwan
- ursodeoxycholic acid
- acetaminophen
- scopolamine
- immune globulin (human)
- rifamycin
- alectinib
- sennosides a&b
- sgm-101
- pantoprazole
- trimebutine
- vancomycin
- capecitabine
- autologous cytokine induced killer cells
- human fecal microbiota
- nexvax2
- docetaxel
- neostigmine
- oxaliplatin
- +10 more
Phase 1 trials (13)
Other trials (51)
- maltodextrin
- propofol
- procaine benzylpenicillin
- capsaicin
- norepinephrine
- goat milk
- lactulose
- indocyanine green
- esketamine
- magnesium oxide
- krill oil
- human milk
- cow milk
- ropivacaine
- honey
- remimazolam
- rifaximin
- fluorescein
- sufentanil
- testosterone
- collagen
- l-epigallocatechin
- gluten
- hou gu mi xi
- hydrolysed whey protein
- oligofructose
- pepsin
- vsl #3
- gentamicin
- algeldrate
- +21 more
Organizations
Organization Involved with Phase 4 Indications (28)
- Sanofi
- Novartis
- GlaxoSmithKline
- Harrison Clinical Research
- Laboratorios Ordesa
- Norgine
- Shenzhen Kangtai Biological Products Co., LTD
- Alexandra Hospital, Athens, Greece
- Cedars-Sinai Medical Center
- China Academy of Chinese Medical Sciences
- Medical University of Warsaw
- Northwestern University
- Universidad Autonoma de Madrid
- Ufuk University
- University of Oslo
- St. Louis University
- University of California, Los Angeles
- University of Naples Frederico II
- Jiao Tong University
- Hospital Joan XXIII de Tarragona, Tarragona, Spain
- Rovira i Virgili University
- Government of China
- Washington University in St. Louis
- CHU Edouard Herriot
- International Clinical Trials Association
- American College of Gastroenterology
- Government of Norway
- Hellenic Society of Gastroenterology
Organization Involved with Phase 3 Indications (42)
- Abbott
- Takeda
- Celgene
- AstraZeneca
- Astra
- Ipsen
- Bellus Health Inc
- Cubist
- Laboratorio Saude Ltda.
- MedVadis Research Corporation
- Valio Ltd
- Sucampo
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Cancer Research Network
- Chang Gung University
- Harvard University
- Nanjing University
- University of Rochester
- University of Toronto
- Chinese University of Hong Kong
- University of California, Irvine
- University of Cincinnati
- Food and Drug Administration
- Sprim Consulting
- The University of Hong Kong
- Research Across America
- AXIS Clinicals Limited
- +12 more
Organization Involved with Phase 2 Indications (51)
- Facet Biotech
- Ironwood Pharmaceuticals
- Bausch Health Companies
- Roche
- Cato Research
- Merck
- Progenics
- Sanofi-Synthelabo
- Shionogi
- Bayer
- Catalysis SL
- Danisco
- Hengrui Therapeutics, Inc.
- HighTide Biopharma Pty Ltd
- ImmusanT, Inc.
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Kyowa Hakko Kirin
- Nordmark Arzneimittel GmbH & Co. KG
- Parexel
- PediaMed Pharmaceuticals
- S-Evans Biosciences Co.,Ltd.
- Shenzhen Hornetcorn Bio-technology Company, LTD
- Boehringer Ingelheim
- Ethicon
- National Center for Research Resources (NCRR)
- Hangzhou Cancer Hospital
- Arizona State University
- Guangzhou Medical University
- Hong Kong Baptist University
- Johns Hopkins University
- +21 more
Organization Involved with Phase 1 Indications (18)
- Novo Nordisk
- Genentech
- Blueprint Medicines Corporation
- Menarini Group
- Maastricht University
- Case Western Reserve University
- Inje University
- University of Groningen
- University of Michigan
- Uppsala University
- CJ HealthCare Corp.
- Free University of Amsterdam
- Conatus Pharmaceuticals
- Karolinska Institute
- Anaheim Clinical Trials
- Top Institute Food and Nutrition
- Children's Hospital Los Angeles
- PvP Biologics, Inc.
Organization Involved with Other Experimental Indications (42)
- Digestive Care, Inc.
- Glycom A/S
- Lesaffre International
- Marigot Ltd.
- Palo Alto Medical Foundation
- ZonMw: The Netherlands Organisation for Health Research and Development
- Children's Hospital of Philadelphia
- Aarhus University
- University of Pennsylvania
- Carle Foundation Hospital
- Carle Physician Group
- University of London
- George Mason University
- Hospital Beatriz Ângelo
- Jiangxi University of Traditional Chinese Medicine
- Norwegian University of Science and Technology
- Ohio State University
- Radboud University
- Stanford University
- Sykehuset Innlandet HF
- University Hospital of North Norway
- University of Nottingham
- Utrecht University
- University of Alberta
- Zagazig University
- Bogomolets National Medical University
- Colorado State University
- Fudan University
- Nanchang University
- University of Calgary
- +12 more